Skip to main contentcrwcwdxryyqbquu

Dr. Miriam and Sheldon G. Adelson Medical Research Foundation


Last Updated: 2016-12-18

At A Glance

Dr. Miriam and Sheldon G. Adelson Medical Research Foundation

300 1st Ave.

Needham, MA United States 02494-2736

Telephone: (781) 972-5900


Type of Grantmaker

Independent foundation

Additional Descriptor

Financial Data

(yr. ended 2015-12-31)

Assets: $627,770

Total giving: $50,977,421






Established in 2006 in MA - Founded by Sheldon G. Adelson and Miriam Adelson. Mr. Adelson is the chairman of the Las Vegas Sands Corp., which owns and operates properties in Las Vegas, including the Venetian Resort Hotel and Casino

Purpose and Activities

Giving primarily to foster collaboration in biomedical research in order to accelerate medical innovation and to facilitate commercialization of innovative medical products for the public good. The foundation is designed to encourage a model in which scientists from different institutions (referred to as Collaborating Scientists) come together to identify and conduct a synergetic group of research studies to answer a particular question (each individual study is referred to as a Component Project and the grouping is referred to as a Collaboration). The Collaborating Scientists determine the sequence, timing, scope and direction of the Component Projects, and the foundation provides infrastructure and financial support to foster the Collaborations and to protect and commercialize resulting biomedical innovation. Currently, the foundation is focusing on collaborations in the areas of neurology, oncology, and immunology.

Program Area(s)

The grantmaker has identified the following area(s) of interest:

Adelson Program in Cancer Research

The program is divided into 3 groups: 1) The Core Cancer Investigator Group within this program consists of experts in basic, clinical and translational research who together possess the comprehensive knowledge required for an iterative and collaborative approach to the identification and validation of novel cancer therapeutic targets and the subsequent clinical testing of agents that interfere with their function; 2) Ubiquitin Proteasome Pathway: The foundation believes that the key role that this regulatory system plays across many cellular processes will lead to new therapies for malignancies, immunological and inflammatory diseases, degenerative diseases of the nervous system, neural regeneration and long-term memory and learning; 3) Melanoma Biomarker Group Collaboration aims to identify the characteristics of subtypes that are most malignant using techniques like those employed by the APCR-Core Cancer group.

Adelson Program in Immunologic Diseases

The goal of this program is to develop novel strategies for target discovery in selected diseases. The first target of the program is Irritable Bowel Disease (IBD). The program will bring together outstanding researchers and physician-scientists who will share their expertise in diverse areas. The strategy will include 1) a thorough and integrated evaluation of patient samples which will allow for better patient stratification and treatment as well as provide mechanistic insights into human disease, 2) constructing new preclinical models in mouse (and perhaps invertebrates) to more faithfully model human disease, 3) create tools and strategies to better understand the control of intestinal epithelial activity and the role of the microbiome in health and disease, and 4) identify novel genetic linkages and therapeutic interactions .

Adelson Program in Neural Repair and Rehabilitation

The Miriam and Sheldon Adelson Program in Neural Repair and Rehabilitation (APNRR) aims to identify the most promising drives for axon regeneration, for the use of stem cells and their differentiated offspring derived from different sources, and for sheathing axon fibers with myelin so they can conduct their electrical pulses. In addition, these scientists aim to manipulate basic mechanisms of learning and memory at synapses to maximize compensation by whatever spared neural networks may remain and to optimize the functional incorporation of restored pathways.he group shares its procedures and biological measures across a variety of models of neurological disease, including spinal cord injury, stroke, brain trauma, ALS, multiple sclerosis, peripheral neuropathies, and optic nerve injury.The APNRR group aims for a proof of concept that biological therapies, medications that act on key targets, and engineering strategies will be able to augment rehabilitation therapies in disabled people. .

Fields of Interest

  • Biomedicine
  • Brain and nervous system disorders
  • Cancers
  • Diseases and conditions
  • Health
  • Neurology
  • Oncology
Population Groups
  • Academics

Financial Data

Year ended 2015-12-31

Assets: $627,770 (market value)

Gifts received: $51,614,409

Expenditures: $52,180,846

Total giving: $50,977,421

Qualifying distributions: $52,133,715